Welcome to our dedicated page for Nakamoto SEC filings (Ticker: NAKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kindly MD, Inc. (NAKA) SEC filings page provides access to the company’s official regulatory disclosures as a publicly traded issuer. KindlyMD, a patient-first and healthcare data company with integrated healthcare services and a Bitcoin treasury strategy via its subsidiary Nakamoto Holdings Inc., uses filings with the U.S. Securities and Exchange Commission to report material events, corporate actions, and financial information.
Among the key documents available are Current Reports on Form 8-K, which the company uses to disclose significant developments. Recent 8-K filings have addressed topics such as the completion of the merger with Nakamoto, entry into and termination of material loan agreements secured by Bitcoin or other digital assets, authorization of a share repurchase program, receipt of a Nasdaq minimum bid price notice, and the establishment of dates and record dates for annual shareholder meetings. These filings also cover matters like redemption of a secured convertible debenture and the company’s financing arrangements with lenders focused on digital assets.
Investors can also review proxy materials, including the Definitive Proxy Statement on Schedule 14A, which outlines proposals submitted to stockholders, such as the election of directors, approval of converting Kindly MD from a Utah corporation to a Delaware corporation, ratification of the independent registered public accounting firm, and potential adjournment of the annual meeting. Notifications of late filing on Form 12b-25 (NT 10-Q) provide context when additional time is needed to complete quarterly reports, including explanations related to the accounting complexity of the merger with Nakamoto.
On Stock Titan, these filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key points, such as new financing obligations, changes in capital structure, or updates on the company’s Bitcoin treasury strategy. Users can quickly locate information about quarterly and annual reporting, material agreements, shareholder votes, and listing status, as well as track how KindlyMD’s integrated healthcare operations and Bitcoin-focused activities are reflected in its regulatory record.
KindlyMD, Inc. filed a 424B7 prospectus listing numerous named selling stockholders who may offer shares of Common Stock registered for resale under the registration statement. The document states the applicable percentage figures are calculated using 413,603,091 shares of Common Stock outstanding as of September 24, 2025. The filing clarifies that the post-offering share amounts assume (a) all Common Stock underlying the Convertible Notes registered in this statement are sold and (b) no other transactions occur before completion of the offering, but also notes each selling stockholder may sell all, some or none of the shares and may use other registration statements or exemptions such as Rule 144.
Jared Barrera, Chief Financial Officer of Kindly MD, Inc. (NAKA), reported a restricted stock award that fully vested on 09/22/2025, resulting in an acquisition of 6,400 shares at no cash price and increasing his beneficial ownership to 22,242 shares. The Form 4, filed by attorney-in-fact on 09/24/2025, shows the transaction was an internal equity award rather than an open-market purchase or sale. The filing includes a standard Exhibit 24 power of attorney signature and does not disclose any cash consideration, option exercises, or derivative transactions.
Kindly MD, Inc. (NAKA) insider reported multiple grants to Chief Medical Officer Timothy Pickett on 09/22/2025. The Form 4 shows four non‑derivative transactions reporting the receipt of 37,593 restricted stock units that vest over four years with a 12‑month cliff, plus three fully vested restricted stock awards of 26,129, 10,146, and 18,378 shares, bringing reported beneficial ownership to 191,271 shares after the transactions. All grants were reported with a $0 price, indicating they are equity awards rather than market purchases. The filing is signed by an attorney‑in‑fact on behalf of the reporting person.
Eric Stanton Weiss, a director of Kindly MD, Inc. (NAKA), was granted 112,781 restricted stock units (RSUs) reported on a Form 4 with a transaction date of 09/22/2025. The RSUs were recorded at a price of $0 and are shown as directly beneficially owned following the grant. The RSUs vest on August 15, 2026 and are subject to Mr. Weiss’s continued service on the company’s board through that Vesting Date. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact, Kyle Simon, on 09/24/2025.
Kindly MD, Inc. (NAKA) director Gregory Elias Xethalis was reported as the sole reporting person on a Form 4 disclosing an award of 112,781 restricted stock units (RSUs) on 09/22/2025. The RSUs are non‑cash, granted at $0 price and are scheduled to vest on August 15, 2026, subject to his continued service on the board through the vesting date. After the reported transaction the filing shows 112,781 shares beneficially owned by the reporting person. The Form is signed by an attorney‑in‑fact on behalf of the reporting person on 09/24/2025.
Amanda Fabiano, Chief Operating Officer of Kindly MD, Inc. (NAKA), reported two grants of restricted stock units on 09/22/2025 that increase her direct beneficial ownership to 4,135,337 shares. One grant covers 751,879 RSUs and the second covers 3,383,458 RSUs; both show a transaction price of $0 and are time-vesting over three years with a 12-month cliff beginning August 15, 2025. After the cliff, 25% vests immediately and the remaining 75% vests in equal quarterly installments over the following 24 months, subject to continued service. The larger grant is further contingent on a performance condition: no shares will vest under that grant unless Fabiano causes Second Gate Advisory, LLC (an entity she owns and controls) to assign or transfer certain business arrangements to the issuer. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Kindly MD, Inc. (NAKA) reports a grant of 751,879 restricted stock units (RSUs) to reporting person David F. Bailey in a transaction dated 09/22/2025. The RSUs vest over four years with a 12-month cliff measured from August 15, 2025: 25% vests at the end of the cliff and the remaining 75% vests in equal quarterly installments over the following 36 months, subject to continued service. After this grant the reporting person beneficially owns 11,912,451 shares. The RSUs have no purchase price reported and are time-based equity compensation intended to align executive incentives with shareholder outcomes.
Kindly MD, Inc. (NAKA) insider report: Chief Commercial Officer Andrew Creighton was granted 601,503 restricted stock units (RSUs) that will time-vest over four years. There is a 12-month cliff from August 15, 2025, after which 25% vests at cliff completion and the remaining 75% vests in equal quarterly installments over the following 36 months, contingent on continued service. After the grant, Mr. Creighton beneficially owns 3,726,474 shares of common stock. The RSUs were granted at no cash price to the reporting person and are subject to the issuer’s standard vesting and service conditions.
Tyler Matthew Evans, Chief Investment Officer of Kindly MD, Inc. (NAKA), was granted 601,503 restricted stock units (RSUs) on 09/22/2025 at a reported price of $0, bringing his total beneficial ownership to 3,012,188 shares. The RSUs vest over four years with a 12-month cliff beginning August 15, 2025, after which 25% vest at the cliff and the remaining 75% vest in equal quarterly installments over the following 36 months. Vesting is contingent on the reporting person’s continued service through each vesting date. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Mark W. Yusko, a director of Kindly MD, Inc. (NAKA), reported an acquisition of 112,781 restricted stock units (RSUs) on 09/22/2025. The filing shows these RSUs were granted at a price of $0 and that the reporting person will beneficially own 2,212,781 shares following the grant. The RSUs vest on August 15, 2026 and are subject to the reporting person ontinuing service on the company oard through that vesting date. The Form 4 was signed and submitted by an attorney-in-fact on behalf of the reporting person.